AllInfo

New Ebola vaccine brings hope in the Congo

At this Moment, many people in the Democratic Republic of the Congo have been waiting for: On Monday a vaccination campaign begins with a new vaccine. This could reach wider layers of the population than in the past.

For over a year, the world’s second-largest Ebola epidemic is raging in the Democratic Republic of the Congo. More than 3200 people have been infected with the Virus. So far, 2144 Infected have died.

But now there are two good news: on the one Hand, the world reports the health organization that the number of reported new infections going back. Only 14 people had been confirmed in the first week of October. That would be the lowest number in a year. At the peak of the epidemic in April 2019, the number of new infections stood at 126 per week.

All the recently reported cases are, therefore, in a relatively limited area, close to the Ugandan border. It is a geographic triangle between the towns of Mambasa/Mandima, Komanda and Oicha. Of all things civil, however, there is a war, which makes it difficult for Doctors and helpers in the work.

More: the struggle for the right vaccination strategy

Tropical doctor, Marylyn Addo is confident that the new vaccine helps the epidemic to limit.

Large population parts in hazard zones

The second piece of good news relates especially to the South in major cities of Beni and Goma: From Monday, 14. October will be using Doctors, there is a new vaccine, the company Johnson & Johnson, which is better than the previous vaccine, VSV-EBOV the company Merck, for a broad prophylaxis.

“The vaccines differ in the strategy but it’s very impressive,” says Marylyn Addo. “With the currently used vaccine you need to vaccinate only once, and the Vaccination occurs very quickly. The new vaccine consists of two components that need to be administered at a distance of eight weeks.”

The Professor heads the section of infectious diseases at the University hospital in Hamburg-Eppendorf at the Bernhard-Nocht-Institute for tropical medicine, emerging infectious diseases.

More on this: Germany supports the fight against Ebola in Africa


“The new vaccine is not for an acute Ebola-suspected case or disease case is actually so good. He will probably be used more in areas that are generally compromised, and in which you could then vaccinate the entire population prophylactically.”

Although the new vaccine is so fast, he has however other advantages. “He can be easily made and must not be chilled so much.” During the previous, fast and effective vaccine by Merck, it must be cooled to minus 60 to 70 degrees, with the new vaccine minus 20 degrees. “These are all advantages. In this respect, we have the hope that we can reach more people,” said Dr. Addo.

More doses of the vaccine available

Because of the ease of manufacture also a lot of people, the new vaccine is expected to to vaccinate: Up to now, have been immunized with the first vaccine, approximately 235,000 people. About twice as many doses of vaccine are currently available.

The new vaccine is about one and a half million doses of the vaccine are now available. Even if the vaccine needs to undergo the Phase III of the marketing authorisation, and so still has to prove itself. “This is of course a possibility, now, to find out whether the vaccine also shows really in the Phase III efficacy. He has shown a very, very good compatibility and also a very good immune response. Therefore, we assume that he protects, but that is not yet occupied,” is infection a researcher Addo to bear in mind.

Therefore, it is now to vaccinate as many people as possible in the four affected cities, as well as in Beni and Goma. So far, these people would have had no Chance to get a vaccination because they belong to the circle of those who direct or indirect contact to Ebola-Sufferers have or have had. “If you would now like to prepare a city for the case of an emergency or if you want to vaccinate health workers – this vaccination provides quite,” said Dr. Addo.

More: WHO: Ebola in Tanzania?

Ebola can skip through the hunting and consumption of wild animals to humans.

Complete Vaccination of the population remains unrealistic

Even if the current Ebola outbreak, hopefully, will be in the near future overcome, the question remains, how in the future against Ebola to be vaccinated, to be for new outbreaks being prepared.

The Problem here is that Ebola is transmitted from wild animals. Since 1967, the Ebola cases have occurred in a vast area in sub-Saharan Africa, from Uganda in the East to Guinea and Sierra Leone in the West of the continent. In between 5000 kilometers nearly. The potential Ebola-risk area, therefore, comprises the hundreds of millions of people. It is therefore clear that The health authorities will vaccinate all people prophylactically, but only on acute outbreaks may respond.

With both vaccines, you now have a good Arsenal of weapons against the Virus. Add to that better drugs for the patients that are already infected. With two antibody therapies, has enabled the Doctors to reduce the mortality rate of Ebola from 67 percent to 35 percent.

“That we know of Ebola only since 1967, are the but great Progress and we have to build on,” says the tropics E. Marylyn Addo confident.

Equally important is not to forget in the face of the fear of Ebola is the more common infectious diseases. These cost a lot more lives. “We have a lot of challenges when it comes to the topic of Vaccination. In the Congo, the world’s largest measles runs just to the outbreak, and there is a very large cholera outbreak.”

More: water shortages complicate the fight against Ebola


Exit mobile version